131 related articles for article (PubMed ID: 38166293)
1. Do depressive and anxiety symptoms influence the construct validity of Multiple Sclerosis Walking Scale-12 scores?
Šilić P; Jones CD; Jeng B; Motl RW
Rehabil Psychol; 2024 May; 69(2):129-134. PubMed ID: 38166293
[TBL] [Abstract][Full Text] [Related]
2. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH
J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065
[TBL] [Abstract][Full Text] [Related]
3. Validation of scores from a telephone administered multiple sclerosis walking scale-12 in persons with multiple sclerosis.
Motl RW; Plummer P; Backus D; Hebert JR; Neal WN; Ng A; Lowman J; Bethoux F; Schmidt H; McBurney R; McCully KK; Cutter G
Mult Scler Relat Disord; 2024 Jun; 88():105715. PubMed ID: 38889558
[TBL] [Abstract][Full Text] [Related]
4. Validity of the 30-Second Sit-to-Stand test as a measure of lower extremity function in persons with multiple sclerosis: Preliminary evidence.
Zheng P; Huynh TLT; Jones CD; Feasel CD; Jeng B; Motl RW
Mult Scler Relat Disord; 2023 Mar; 71():104552. PubMed ID: 36774829
[TBL] [Abstract][Full Text] [Related]
5. Self-efficacy and Walking Performance in Persons With Multiple Sclerosis.
Motl RW; Balto JM; Ensari I; Hubbard EA
J Neurol Phys Ther; 2017 Apr; 41(2):114-118. PubMed ID: 28263255
[TBL] [Abstract][Full Text] [Related]
6. Further validation of multiple sclerosis walking scale-12 scores based on spatiotemporal gait parameters.
Pilutti LA; Dlugonski D; Sandroff BM; Suh Y; Pula JH; Sosnoff JJ; Motl RW
Arch Phys Med Rehabil; 2013 Mar; 94(3):575-8. PubMed ID: 22960049
[TBL] [Abstract][Full Text] [Related]
7. Results of a feasibility and initial efficacy clinical trial of a high-intensity interval training program using adaptive equipment in persons with multiple sclerosis who have walking disability.
Silveira SL; Motl RW; Elmer DJ; Botkin T; Ontiveros T; Williams S; Hubbard EA
Mult Scler Relat Disord; 2024 Jul; 87():105695. PubMed ID: 38820697
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic correlates of six-minute walk performance in persons with multiple sclerosis.
Motl RW; Balantrapu S; Pilutti L; Dlugonski D; Suh Y; Sandroff BM; Lane A; Fernhall B
Eur J Phys Rehabil Med; 2013 Feb; 49(1):59-66. PubMed ID: 22820825
[TBL] [Abstract][Full Text] [Related]
9. No association between body composition and walking outcomes in multiple sclerosis.
Jeng B; Motl RW
Mult Scler Relat Disord; 2022 Dec; 68():104242. PubMed ID: 36274282
[TBL] [Abstract][Full Text] [Related]
10. Validity of minimal clinically important difference values for the multiple sclerosis walking scale-12?
Motl RW; Learmonth YC; Pilutti LA; Dlugonski D; Klaren R
Eur Neurol; 2014; 71(3-4):196-202. PubMed ID: 24457548
[TBL] [Abstract][Full Text] [Related]
11. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
[TBL] [Abstract][Full Text] [Related]
12. Accelerometry as a measure of walking behavior in multiple sclerosis.
Motl RW; Pilutti L; Sandroff BM; Dlugonski D; Sosnoff JJ; Pula JH
Acta Neurol Scand; 2013 Jun; 127(6):384-90. PubMed ID: 23240822
[TBL] [Abstract][Full Text] [Related]
13. The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory.
Engelhard MM; Schmidt KM; Engel CE; Brenton JN; Patek SD; Goldman MD
Qual Life Res; 2016 Dec; 25(12):3221-3230. PubMed ID: 27342237
[TBL] [Abstract][Full Text] [Related]
14. Translation and validation of the multiple sclerosis walking scale 12 for the German population - the MSWS-12/D.
Chorschew A; Kesgin F; Bellmann-Strobl J; Flachenecker P; Schiffmann I; Rosenthal F; Althoff P; Drebinger D; Arsenova R; Rasche L; Dorsch EM; Heesen C; Paul F; Stellmann JP; Schmitz-Hübsch T
Health Qual Life Outcomes; 2023 Oct; 21(1):110. PubMed ID: 37814258
[TBL] [Abstract][Full Text] [Related]
15. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
16. Self-efficacy and walking performance across the lifespan among adults with multiple sclerosis.
Sikes EM; Cederberg KL; Baird JF; Sandroff BM; Motl RW
Neurodegener Dis Manag; 2019 Oct; 9(5):267-275. PubMed ID: 31580224
[No Abstract] [Full Text] [Related]
17. Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12).
Motl RW; Snook EM
J Neurol Sci; 2008 May; 268(1-2):69-73. PubMed ID: 18061618
[TBL] [Abstract][Full Text] [Related]
18. The impact of smoking cessation on multiple sclerosis disease progression.
Rodgers J; Friede T; Vonberg FW; Constantinescu CS; Coles A; Chataway J; Duddy M; Emsley H; Ford H; Fisniku L; Galea I; Harrower T; Hobart J; Huseyin H; Kipps CM; Marta M; McDonnell GV; McLean B; Pearson OR; Rog D; Schmierer K; Sharrack B; Straukiene A; Wilson HC; Ford DV; Middleton RM; Nicholas R
Brain; 2022 May; 145(4):1368-1378. PubMed ID: 34623418
[TBL] [Abstract][Full Text] [Related]
19. Do multiple sclerosis symptoms moderate the relationship between self-efficacy and physical activity in people with multiple sclerosis?
Casey B; Uszynski M; Hayes S; Motl R; Gallagher S; Coote S
Rehabil Psychol; 2018 Feb; 63(1):104-110. PubMed ID: 29553785
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Korean Version of the 12-Item Multiple Sclerosis Walking Scale and Application to Neuromyelitis Optica Spectrum Disorder.
Kim W; Park EY; Hyun JW; Huh SY; Park NY; Jang H; Kim SH; Kim HJ
J Clin Neurol; 2020 Apr; 16(2):270-276. PubMed ID: 32319244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
